Pharmaceutics articles list

Furosemide is a widely potent diuretic drug used in the management of edema and hypertension. Various brands of furosemide are available in the Libyan market and should be subjected to different quality control tests to assess their pharmaceutical equivalence. This study aimed to assess and compare the quality and the pharmaceutical equivalence of some generic brands of furosemide 40 mg tablets marketed in Libya. The pharmaceutical quality of four brands of furosemide tablets was investigated using official and unofficial compendia standards including uniformity of weight, friability, thickness, hardness, drug content and dissolution rate. The results obtained showed acceptable external features as well as the thickness, diameter and uniformity of weight for all the furosemide tablets. The tested brands complied with the official specifications of friability, hardness and drug content. In conclusion, all four brands can be considered as bioequivalence and thus can be pharmaceutically substituted in clinical practice.

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Diabetes mellitus is a common and chronic metabolic disorder. Uncontrolled diabetes mellitus leads to body organ damage if not treated properly. Educational intervention is necessary from health-care providers such as pharmacists to prevent or reduce organ damage and complications among the diabetic patients. Several studies have demonstrated the contribution of pharmacists in achieving a better control of diabetes mellitus. Thus, this study intended to assess the knowledge and practice regarding foot care among Libyan diabetic patients in Al-Bayda city. In addition, to determine the association between knowledge and practice regarding diabetic foot care with selected demographic variables. This is a cross sectional study conducted at Diabetes Center Aljabal Al akhdar in Al-Bayda between April and August, 2022. A total of 400 participants with diabetes were enrolled and interviewed by using a self-design questionnaire for knowledge and practice of foot care after taking verbal agreement. Data was analyzed by using SPSS software version 26.0. In this study, 191 subjects were male (47.8%) and 209 subjects (52.3%) were female. On the topic of foot care, 51.8% of the participants stated they did know how to perform correct foot hygiene and 33.5% stated that drying should consist of passing a towel between their toes. Female subjects statistically had more knowledge than male subjects on the right footwear and correct way of nail cutting (p < 0.01 and p < 0.001, respectively). In relation to practice, the frequency of patients with a good practice was 126 (31.5%) and with poor practice was 274 (68.5%). Evaluating the parameters dry, moisturize and nail cutting, women showed a significant difference in relation to men, with a high significance level in the three parameters. In conclusion, the knowledge and practice of foot care in Libyan patients with diabetes were poor. So, an educational program is recommended to improve the awareness of foot care. Diabetic patients should be provided information about self-care of their feet by health care providers such as pharmacists to prevent and delay onset of foot complications and improve the quality of life.

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Chronic kidney disease is a public health problem affecting people worldwide. This study was aimed to examine the characteristics of patients with chronic kidney disease and to identify prevalence of drug-related problems among Libyan patients. This is a descriptive retrospective study carried out in Southern-west part of Libya, Sebha City. Information abstraction forms were used for collection of data. The investigators reviewed the medications, medical records and laboratory data to identify drug-related problems.1 000 patients' files during 2019-2020 were examined and only 120 files were selected for this study. The majority of the participants were male (73, 61.0%) and the mean age was 56.1 years. 576 comorbidities among the selected patients were identified (73.61%) and the average number per patients was 4.8 concurrent diseases. There were 1 350 medications prescribed and the average of prescribed drugs per patient was 11.25. The majority of patients use more than 10 drugs (64, 53.3%) and the average length of staying in the hospital was 5.58 days. 502 drug-related problems were identified with an average of 4.18 per patient. Untreated conditions such as Hyponatremia and anemia were the highest rate of drug-related problems identified (199, 39.6%) followed by improper drug selection (82, 16.3%) such as cefotaxime, vancomycin and aminoglycoside for chronic kidney disease and drug use without indications such as antibiotics (68, 13.5%) and over-therapeutic dose such as metoclopramide(63, 12.5%). In conclusion, all the patients have polypharmacy and the majority have comorbid conditions and chronic kidney disease with frequent drug-related problems, thus, to lower the incidence rate of drug-related problems, therapeutic interventions are needed. Subsequently, it is a crucial to involve clinical pharmacist in hospital to improve the care of patient with chronic kidney disease.

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

This work was focused on identification and evaluation of process parameters of modified nanoprecipitation method, for fabrication of lomustine nanoparticles, with the aim of reducing cancer cell viability at low concentration of lomustine. The parameters controlling particle size, mostly in nanosize, were solvent/nonsolvent composition and emulsification speed of homogenizer along with aqueous phase volume. This controlled particle size is below 250 nm. The stabilizer concentration controlled particle size is within 68 nm ± 0.89 to 137 ± 0.94 nm with PDI 0.06 ± 0.008 to 0.25 ± 0.001. But, the stabilizer addition mode showed more uniform size distribution with PDI 0.085 ± 0.004. Entrapment efficiency was maintained well above 47 ± 0.23%. The drug release pattern was monophasic with controlled release over 24 hrs. In the method used, drug content was affected by ratio of polymer to drug to organic solvent, as well as homogenization speed and time. Percentage viable cells of L132 human lung cancer cell line remained, were only 5% at 100 μg/ml lomustine equivalent PLA nanoparticles.

Archana Mehrotra

The incorporation of lomustine, a hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition method was optimized. Based on the optimal parameters, it was found that lomustine-PLGA nanoparticles with acceptable properties could be obtained. Optimization of formulation variables to control the size and drug entrapment efficiency of the prepared nanoparticles seems to be based on the same scientific principles as drug-loaded nanoparticles prepared by nanoprecipitation, solvent evaporation method. The process was the most important factor to control the particle size, while both the drug-polymer interaction and the partition of drug in organic and aqueous phases were the crucial factors to govern the drug entrapment efficiency. PLGA concentration at lower level (100 mg), 1:5 organic phase: aqueous ratio, 1%w/v PVA concentration, 3%w/v pluronic F68 achieved smaller particle size. Additionally, L:G ratio of PLGA 75:25, lower volume of organic solvent (1:10 organic phase: aqueous phase), higher initial drug content (10mg) enhanced the drug entrapment efficiency and maintained lomustine concentration in blood for an extended time period, elevated lomustine concentration in lungs and slowed the elimination of lomustine. The biodistribution profiles of prepared nanoparticles in albino mice showed higher plasma drug concentration for longer period of time, elevated drug concentration in lungs and slow elimination from kidney. No toxic effects of prepared nanoparticles were observed in histopathological examination of lungs and kidney. The systematic investigation reported here promises the development of PLGA nanoparticles loaded with lomustine when tested in Lung Cancer cell line L132 and toxicological/ histopathological studies in albino mice.

Archana Mehrotra

This work was focused on identification and evaluation of process parameters of modified nanoprecipitation method, for fabrication of lomustine nanoparticles, with the aim of reducing cancer cell viability at low concentration of lomustine. The parameters controlling particle size, mostly in nanosize, were solvent/nonsolvent composition and emulsification speed of homogenizer along with aqueous phase volume. This controlled particle size is below 250 nm. The stabilizer concentration controlled particle size is within 68 nm ± 0.89 to 137 ± 0.94 nm with PDI 0.06 ± 0.008 to 0.25 ± 0.001. But, the stabilizer addition mode showed more uniform size distribution with PDI 0.085 ± 0.004. Entrapment efficiency was maintained well above 47 ± 0.23%. The drug release pattern was monophasic with controlled release over 24 hrs. In the method used, drug content was affected by ratio of polymer to drug to organic solvent, as well as homogenization speed and time. Percentage viable cells of L132 human lung cancer cell line remained, were only 5% at 100 μg/ml lomustine equivalent PLA nanoparticles.

Archana Mehrotra

The incorporation of lomustine, a hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition method was optimized. Based on the optimal parameters, it was found that lomustine-PLGA nanoparticles with acceptable properties could be obtained. Optimization of formulation variables to control the size and drug entrapment efficiency of the prepared nanoparticles seems to be based on the same scientific principles as drug-loaded nanoparticles prepared by nanoprecipitation, solvent evaporation method. The process was the most important factor to control the particle size, while both the drug-polymer interaction and the partition of drug in organic and aqueous phases were the crucial factors to govern the drug entrapment efficiency. PLGA concentration at lower level (100 mg), 1:5 organic phase: aqueous ratio, 1%w/v PVA concentration, 3%w/v pluronic F68 achieved smaller particle size. Additionally, L:G ratio of PLGA 75:25, lower volume of organic solvent (1:10 organic phase: aqueous phase), higher initial drug content (10mg) enhanced the drug entrapment efficiency and maintained lomustine concentration in blood for an extended time period, elevated lomustine concentration in lungs and slowed the elimination of lomustine. The biodistribution profiles of prepared nanoparticles in albino mice showed higher plasma drug concentration for longer period of time, elevated drug concentration in lungs and slow elimination from kidney. No toxic effects of prepared nanoparticles were observed in histopathological examination of lungs and kidney. The systematic investigation reported here promises the development of PLGA nanoparticles loaded with lomustine when tested in Lung Cancer cell line L132 and toxicological/ histopathological studies in albino mice.

Archana Mehrotra

The incorporation of lomustine, a hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition method was optimized. Based on the optimal parameters, it was found that lomustine-PLGA nanoparticles with acceptable properties could be obtained. Optimization of formulation variables to control the size and drug entrapment efficiency of the prepared nanoparticles seems to be based on the same scientific principles as drug-loaded nanoparticles prepared by nanoprecipitation, solvent evaporation method. The process was the most important factor to control the particle size, while both the drug-polymer interaction and the partition of drug in organic and aqueous phases were the crucial factors to govern the drug entrapment efficiency. PLGA concentration at lower level (100 mg), 1:5 organic phase: aqueous ratio, 1%w/v PVA concentration, 3%w/v pluronic F68 achieved smaller particle size. Additionally, L:G ratio of PLGA 75:25, lower volume of organic solvent (1:10 organic phase: aqueous phase), higher initial drug content (10 mg) enhanced the drug entrapment efficiency and maintained lomustine concentration in blood for an extended time period, elevated lomustine concentration in lungs and slowed the elimination of lomustine. The biodistribution profiles of prepared nanoparticles in albino mice showed higher plasma drug concentration for longer period of time, elevated drug concentration in lungs and slow elimination from kidney. No toxic effects of prepared nanoparticles were observed in histopathological examination of lungs and kidney. The systematic investigation reported here promises the development of PLGA nanoparticles loaded with lomustine when tested in Lung Cancer cell line L132 and toxicological/ histopathological studies in albino mice.

Archana Mehrotra

This study was aimed to develop lomustine loaded chitosan nanoparticles using a homogenization and spray drying technique. Effect of crosslinking agents (sodium tripolyphosphate (TPP), and sodium hexametaphosphate (HMP)) were studied on the leaching of drug, water uptake of hydrogels, drug release from matrix and its mechanism. Nanoparticles were obtained in the average size range of 111±16.2 to 942±11.7 nm with polydispersity index (PDI) from 0.116±0.039 to 0.517±0.037. Zeta potential of nanoparticles was ranged from 29.0±1.1 to 56.0±1.1 mV. The % encapsulation effi ciency of nanoparticles ranged between 58±0.88% and 96±0.51%.nanoparticles were coated with PEG 6000 to modulate drug release. Swelling index of chitosan-TPP and chitosan-TPP-PEG nanoparticles was about 428% and 350% over the 4 h and it was more (about 465% and 395%) for chitosan-HMP and chitosan-HMP-PEG nanoparticles. Drug release was sustained and diffusion controlled. Optimized formulation was tested for anticancer activity and drug retention study. Cytotoxicity on human lung cancer cell line L132 was studied by trypan blue dye exclusion test. Drug loaded nanoparticles killed L132 cells more effi ciently than the corresponding drug alone (p< 0.05). Due to the increased surface area lomustine loaded TPP and HMP crosslinked chitosan nanoparticles showed better anticancer activity.

Archana Mehrotra

The present study describes the use of an aqueous solution containing a blend of hydrotropic solubilizing agents (mixed hydrotropic substance’s solution) as a successful solvent system utilizing the concept of mixed hydrotropy for spectrophotometric analytical estimation of various conventional formulations as well as novel drug delivery systems. Frusemide, a poorly water-soluble drug, was estimated by application of mixed hydrotropic solubilization method. There was more than 15-fold enhancement in aqueous solubility of frusemide in a solution of blend of hydrotropic agents which consisted of 30% urea, 13.6% sodium acetate and 11.8% sodium citrate. This solvent mixture was employed to solubilize the drug from the fine powder of tablet formulations as well as the niosomes of frusemide. The selected λmax for spectrophotometric estimation was 333 nm. The hydrotropic agents used in the analysis and additives used in the manufacture of tablets and preparation of niosomes did not interfere in the analysis. Statistical data proved the accuracy, reproducibility and precision of the proposed method. The results suggested that proposed method is new, rapid, simple, accurate, and reproducible as well as employed aqueous solvent instead of organic solvents in estimation of drug from the dosage forms.

Archana Mehrotra

The use of spectroscopic analysis, particularly UV spectrophotometer, is a simple and essential technique for bulk drug estimation, formulation studies, and compatibility assessments of drugs with various excipients. In the pharmaceutical industry, various analytical instruments, including Fourier transform infrared spectroscopy (FTIR), are employed for investigating drug-excipient interactions that can impact the stability of active pharmaceutical ingredients. This study aimed to develop a UV spectrophotometric method for the analysis of Pioglitazone hydrochloride in phosphate buffer (pH 7.4) and methanolic solution, assessing its linearity and compliance with Beer's Law. Furthermore, we aimed to use FTIR to characterize potential interactions between Pioglitazone and common pharmaceutical excipients, such as Guar Gum, Chitosan, and Sodium Alginate. Standard solutions of Pioglitazone were prepared in phosphate buffer (pH 7.4) and methanol. UV spectrophotometer was conducted to determine the maximum absorption wavelength. Calibration curves were constructed to evaluate linearity and adherence to Beer's Law. FTIR analyses were performed to investigate drug-excipient interactions by examining the functional groups. In phosphate buffer (pH 7.4), the maximum absorption wavelength for Pioglitazone hydrochloride was 268 nm. The calibration curve for Pioglitazone in phosphate buffer (pH 7.4) demonstrated linearity in the concentration range of 1–20 μg/ml, with a correlation coefficient of 0.998. In methanol, the maximum absorption wavelength for Pioglitazone hydrochloride was found to be 272 nm. The calibration curve in methanol exhibited linearity in the range of 1–20 μg/ml, with a correlation coefficient of 0.999. FTIR analysis revealed potential drug-excipient interactions, particularly in the case of Guar Gum, Chitosan, and Sodium Alginate, suggesting the formation of stable hydrogen bonds. The developed UV spectrophotometric method for Pioglitazone analysis is a reliable, cost- effective, and reproducible approach, making it a valuable tool for drug development and quality control. Additionally, the FTIR characterization confirmed interactions between Pioglitazone and common pharmaceutical excipients, enhancing our understanding of formulation compatibility,

Archana Mehrotra

Most of mosquito-repellent products and devices are made up of synthetic materials presenting market which causes various harmful effects on human beings. The resistance can be developed by the mosquito due to continuous exposure at high doses. Hence, the present research work represents the development and evaluation of mosquito repellent sticks with the help of various herbal products such as starch powder, wood powder, charcoal powder, eucalyptus oil, coconut oil, lavender oil, lemongrass and cinnamon oil, peppermint and citronella, neem oil making them ozone-friendly, financial effective, non-harmful.

Archana Mehrotra

Dry powder injection of spironolactone was developed using lyophilization and hydrotropic solubilization method. It is fast acting medication in emergencies like refractory edema associated with heart failure and hepatic cirrhosis. The ultimate aqueous based powder prepared showed 892.85 and 378.57 times increased solubility of spironolactone with sodium salicylate and sodium benzoate as compared to its water solubility. Amongst six hydrotropic agents, the solubility was increased in the order sodium salicylate > sodium benzoate > nicotinamide > sodium ascorbate > urea > sodium acetate. IR graph showed shift of wavenumber of characteristic peaks. Lyophilization technique produced more stable product against different temperature cycles and stability parameters. Degradation was only about 0.45% at room temperature and it was more about 1.3% at higher temperatures. Haemolytic activities of lyophilized formulations observed were 8.54% to 96.85% for sodium salicylate based hydrotropic lyophilized system and 3.50 to 88.17% for sodium salicylate based hydrotropic lyophilized system.

Archana Mehrotra